XML 42 R18.htm IDEA: XBRL DOCUMENT v3.22.4
SUPPLEMENTAL CASH FLOW AND OTHER DATA
12 Months Ended
Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]  
SUPPLEMENTAL CASH FLOW AND OTHER DATA SUPPLEMENTAL CASH FLOW AND OTHER DATA
    Supplemental cash flow and other data for the years ended December 31, 2022, 2021 and 2020 was as follows:
    
202220212020
Depreciation expense$317 $305 $258 
Amortization expense120 103 103 
Depreciation and amortization expense$437 $408 $361 
Interest expense$(148)$(152)$(166)
Interest income10 
Interest expense, net$(138)$(151)$(163)
Interest paid$156 $159 $201 
Income taxes paid$283 $709 $360 
Accounts payable associated with capital expenditures$38 $26 $46 
Accounts payable associated with purchases of treasury stock$— $23 $— 
Dividend payable$74 $74 $76 
Dividends received from equity method investees$61 $60 $54 
Businesses acquired:  
Fair value of assets acquired$182 $364 $368 
Fair value of liabilities assumed16 18 17 
Fair value of net assets acquired166 346 351 
Merger consideration payable(18)(15)— 
Cash paid for business acquisitions148 331 351 
Less: Cash acquired— 21 
Business acquisitions, net of cash acquired$144 $331 $330 

202220212020
Leases:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$185 $185 $185 
Operating cash flows from finance leases$$$
Financing cash flows from finance leases$$$
Leased assets obtained in exchange for new operating lease liabilities$154 $150 $219 

    During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $31 million operating lease right-of-use asset.

    During the years ended December 31, 2022, 2021 and 2020, costs associated with donations, contributions, and other financial support through Quest for Health Equity, the Company's initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, were $93 million, $16 million and $2 million, respectively. Such amounts are included in selling, general and administrative expenses in the Company's consolidated statement of operations. Costs incurred during the year ended December 31, 2022 will be donated and contributed over several years.